Analysis of the Availability of Anti-Myeloma Drugs and Impact on the Current Management of Myeloma in Latin American Countries

Simple item page
dc.contributor.authorRoberto José Pessoa de Magalhães Filho
dc.contributor.authorEdvan de Queiroz Crusoé
dc.contributor.authorWillen Bujan
dc.contributor.authorEloísa Riva
dc.contributor.authorGuilhermo Ruiz Arguelles
dc.contributor.authorJuan Ramon Navarro Cabrera
dc.contributor.authorDiana Katerine Garcia
dc.contributor.authorGuilhermo e Quintero Vega
dc.contributor.authorGuilhermo Conte
dc.contributor.authorJosé Antonio Rosendo Macías
dc.coverage.spatialBolivia
dc.date.accessioned2026-03-22T15:16:07Z
dc.date.available2026-03-22T15:16:07Z
dc.date.issued2017
dc.descriptionCitaciones: 3
dc.identifier.doi10.1016/j.clml.2017.03.026
dc.identifier.urihttps://doi.org/10.1016/j.clml.2017.03.026
dc.identifier.urihttps://andeanlibrary.org/handle/123456789/51372
dc.language.isoen
dc.publisherElsevier BV
dc.relation.ispartofClinical Lymphoma Myeloma & Leukemia
dc.sourceUniversidade Federal do Rio de Janeiro
dc.subjectPomalidomide
dc.subjectCarfilzomib
dc.subjectMultiple myeloma
dc.subjectBortezomib
dc.subjectThalidomide
dc.subjectMedicine
dc.subjectLenalidomide
dc.subjectLatin Americans
dc.subjectFamily medicine
dc.subjectBusiness
dc.titleAnalysis of the Availability of Anti-Myeloma Drugs and Impact on the Current Management of Myeloma in Latin American Countries
dc.typearticle

Files

Collections

Artículo Científico Publicado